GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LianBio (OTCPK:LIANY) » Definitions » Financial Strength

LianBio (LianBio) Financial Strength : 7 (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is LianBio Financial Strength?

LianBio has the Financial Strength Rank of 7.

Good Sign:

LianBio shows strong financial strength.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

GuruFocus does not calculate LianBio's interest coverage with the available data. As of today, LianBio's Altman Z-Score is 0.00.


Competitive Comparison of LianBio's Financial Strength

For the Biotechnology subindustry, LianBio's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LianBio's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LianBio's Financial Strength distribution charts can be found below:

* The bar in red indicates where LianBio's Financial Strength falls into.



LianBio Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

LianBio's Interest Expense for the months ended in Sep. 2023 was $0.00 Mil. Its Operating Income for the months ended in Sep. 2023 was $-26.30 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.95 Mil.

LianBio's Interest Coverage for the quarter that ended in Sep. 2023 is

GuruFocus does not calculate LianBio's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. LianBio has enough cash to cover all of its debt. Its financial situation is stable.

2. Debt to revenue ratio. The lower, the better.

LianBio's Debt to Revenue Ratio for the quarter that ended in Sep. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Sep. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.893 + 0.95) / 0
=N/A

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

LianBio has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LianBio  (OTCPK:LIANY) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

LianBio has the Financial Strength Rank of 7.


LianBio Financial Strength Related Terms

Thank you for viewing the detailed overview of LianBio's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


LianBio (LianBio) Business Description

Traded in Other Exchanges
N/A
Address
103 Carnegie Center Drive, Suite 215, Princeton, NJ, USA, 08540
LianBio is a science-driven biopharmaceutical company dedicated to developing and commercializing medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets. It is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease, and respiratory indications.
Executives
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Wei Wei Chen director C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 309, PRINCETON NJ 08540
Debra Yu officer: See Remarks C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
C2 Life Sciences Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Lev Lb Holdings Gp, Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Venture Advisors, Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Susan Michele Silbermann director C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Brianne Jahn officer: Chief Business Officer C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Yizhe Wang director, officer: Chief Executive Officer 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Jiang Qian officer: China General Manager C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Lev Lb Holdings, Lp 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Xontogeny Venture Fund, Lp 10 percent owner C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Yi Larson officer: Chief Financial Officer C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Neil Kumar director C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304